News Quantified

MAZE – maze therapeutics, inc. (US:NASDAQ)

Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at BTIG Research from $37.00 to $46.00. They now have a "buy" rating on the stock.

1/16

03:48 am

maze

Low

Maze Therapeutics: An Innovative, Nature-Driven Platform [Seeking Alpha]

What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% [Yahoo! Finance]

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}